Volume 141, Issue 6, Pages (December 2011)

Slides:

Advertisements

Similar presentations

Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:

Advertisements

SVR4 and SVR12 with an interferon-free regimen of BI AND BI , +/- ribavirin, in treatment-naïve patients with chronic genotype-1 HCV infection:

Ashutosh Gupta, Bashar M. Attar, Vikram Kotwal

Volume 149, Issue 6, Pages (November 2015)

Volume 148, Issue 2, Pages e1 (February 2015)

Report of an International Workshop: Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B Emmet B. Keeffe, Stefan Zeuzem,

Volume 139, Issue 4, Pages (October 2010)

Chronic Hepatitis C Therapy: Changing the Rules of Duration

Volume 131, Issue 2, Pages (August 2006)

Nathalie Adda, Doug J. Bartels, Linda Gritz, Tara L

Covering the Cover Gastroenterology

Volume 149, Issue 6, Pages (November 2015)

New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges

Effectiveness of Hepatitis B Treatment in Clinical Practice

Is HCV Infection a Neurologic Disorder?

Volume 146, Issue 3, Pages e1 (March 2014)

Volume 143, Issue 3, Pages e5 (September 2012)

Volume 132, Issue 1, Pages (January 2007)

Improved Virologic Response in Chronic Hepatitis C Genotype 4 Treated With Nitazoxanide, Peginterferon, and Ribavirin Jean–François Rossignol, Asem Elfert,

Ira J. Fox, Stephen C. Strom Gastroenterology

Volume 59, Issue 4, Pages (October 2013)

Volume 141, Issue 3, Pages e1 (September 2011)

Amnon Sonnenberg, Richard H. Lash, Robert M. Genta Gastroenterology

Volume 142, Issue 4, Pages (April 2012)

Volume 146, Issue 2, Pages (February 2014)

Oral Bisacodyl Is Effective and Well-Tolerated in Patients With Chronic Constipation Michael A. Kamm, Stefan Mueller–Lissner, Arnold Wald, Erika Richter,

Michael Biermer, Thomas Berg Gastroenterology

A Historical Perspective on Clinical Advances in Pancreatic Diseases

Volume 150, Issue 4, Pages (April 2016)

Volume 146, Issue 3, Pages e3 (March 2014)

Report of an International Workshop: Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B Emmet B. Keeffe, Stefan Zeuzem,

Volume 155, Issue 5, Pages e2 (November 2018)

Volume 141, Issue 5, Pages (November 2011)

Volume 146, Issue 7, Pages e3 (June 2014)

Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV.

Volume 152, Issue 1, Pages e4 (January 2017)

Volume 138, Issue 1, Pages (January 2010)

Volume 130, Issue 4, Pages (April 2006)

Volume 145, Issue 5, Pages e5 (November 2013)

Volume 135, Issue 5, Pages (November 2008)

New HCV therapies on the horizon

Ashutosh Gupta, Bashar M. Attar, Vikram Kotwal

Christoph Sarrazin, Stefan Zeuzem Gastroenterology

Volume 127, Issue 5, Pages (November 2004)

Volume 142, Issue 6, Pages (May 2012)

Volume 141, Issue 1, Pages (July 2011)

Rafael Esteban, Maria Buti Gastroenterology

Chronic Hepatitis C Therapy: Changing the Rules of Duration

Volume 140, Issue 7, Pages (June 2011)

Volume 133, Issue 2, Pages (August 2007)

Low-Dose Peginterferon Alfa-2a Is Safe and Produces a Sustained Virologic Response in Patients With Chronic Hepatitis C and End-Stage Renal Disease Markus.

Volume 145, Issue 4, Pages e3 (October 2013)

Ashwin N. Ananthakrishnan, David Lieberman Gastroenterology

Volume 137, Issue 6, Pages (December 2009)

Volume 148, Issue 2, Pages e1 (February 2015)

Volume 139, Issue 6, Pages (December 2010)

Statin Therapy Improves Sustained Virologic Response Among Diabetic Patients With Chronic Hepatitis C Gowtham A. Rao, Prashant K. Pandya Gastroenterology

The Dawning of a New Editorial Board for Gastroenterology

Volume 143, Issue 3, Pages e5 (September 2012)

Alessio Aghemo, Maria Francesca Donato Gastroenterology

Volume 147, Issue 2, Pages e1 (August 2014)

Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection Harald Farnik, Christian M. Lange,

Volume 156, Issue 3, Pages (February 2019)

Clinical Gastroenterology and Hepatology

Volume 155, Issue 6, Pages (December 2018)

Eradication Therapy for Helicobacter pylori

Volume 139, Issue 6, Pages e1 (December 2010)

Volume 139, Issue 5, Pages (November 2010)

Detection of HCV RNA in Sustained Virologic Response to Direct-Acting Antiviral Agents: Occult or Science Fiction? Masaru Enomoto, Yoshiki Murakami,

The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus.

Presentation transcript:

Volume 141, Issue 6, Pages 2047-2055 (December 2011) Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection Stefan Zeuzem, Tarik Asselah, Peter Angus, Jean–Pierre Zarski, Dominique Larrey, Beat Müllhaupt, Ed Gane, Marcus Schuchmann, Ansgar Lohse, Stanislas Pol, Jean–Pierre Bronowicki, Stuart Roberts, Keikawus Arasteh, Fabien Zoulim, Markus Heim, Jerry O. Stern, George Kukolj, Gerhard Nehmiz, Carla Haefner, Wulf Otto Boecher Gastroenterology Volume 141, Issue 6, Pages 2047-2055 (December 2011) DOI: 10.1053/j.gastro.2011.08.051 Copyright © 2011 AGA Institute Terms and Conditions

Figure 1 Trial schema. eRVR, extended rapid virologic response (HCV RNA level ≤25 IU/mL at week 4, and HCV RNA undetectable from weeks 5 to 18); QD, once daily; TID, 3 times daily. Gastroenterology 2011 141, 2047-2055DOI: (10.1053/j.gastro.2011.08.051) Copyright © 2011 AGA Institute Terms and Conditions

Figure 2 Patient disposition. Gastroenterology 2011 141, 2047-2055DOI: (10.1053/j.gastro.2011.08.051) Copyright © 2011 AGA Institute Terms and Conditions

Figure 3 Absolute HCV RNA level from baseline to day 29 for individual patients in (A) the BI 207127 400 mg dose group and (B) the BI 207127 600 mg dose group. *Patient with virologic breakthrough observed during treatment at day 22. **Patient with an increase in HCV RNA from nadir of 0.7 log10 IU/mL. LLOD, 17 IU/mL; LLOQ, 25 IU/mL. Gastroenterology 2011 141, 2047-2055DOI: (10.1053/j.gastro.2011.08.051) Copyright © 2011 AGA Institute Terms and Conditions